04.18.25 -- Upgrading The Vial/Vein-To-Vein Process With Enterprise-Level Digital Infrastructure

Learn about adaptive design (AD) trials that reduce clinical trial time and cost while enhancing patient safety by minimizing exposure to unsafe or ineffective treatments.

Overcoming barriers to gene therapy development requires continued innovation in manufacturing processes, harmonized regulatory approaches, and outcome-based pricing models.

OpenClinica Recruit offers a flexible, user-friendly participant management system with real-time tracking and transparent pricing.

The Regional Site Manager (RSM) monitoring model eliminates numerous clinical trial risks by leveraging efficient, start-to-finish site management by a single, expert point of contact.

Explore the findings of a survey of 124 U.S. oncologists focused on better understanding the current use of cell and gene therapies (CGTs) and possible barriers to future adoption.

Stem cell therapy has already revolutionized the field of oncology. But where do we go from here? Dr. Robert S. Negrin addresses three key areas of CAR T-cell therapy on the brink of innovation.

Home trial support services can play a significant role in improving patient access and engagement across a range of studies.

As CGT developers gain knowledge about their processes, single-use technologies (SUT) manufacturers can better address the sector's unique autologous needs by adapting to smaller volume production.